On behalf of her client Jarrow Formulas Inc., a major dietary supplement company, Shareholder Susan Brienza co-authored a formal Comment to the FDA on the agency’s revised guidance on New Dietary Ingredients (NDIs). Filed on December 12, 2016, these Comments were very important to the supplement industry as a whole because the FDA’s current policy on NDIs would require an exorbitant and burdensome pre-market filing that would stifle innovative new products. This guidance document is the most recent instance of improper overreach and overregulation by the Agency, which is a major concern for the supplement industry.
Read this NutraIngredients article for more details about the Comment submitted on behalf of Jarrow Formulas.